The Paradigm Shift in Metastatic Prostate Cancer Management
Historically, the management of metastatic prostate cancer (mPC) was centered almost exclusively on systemic androgen deprivation therapy (ADT). The presence of distant spread was traditionally viewed as a systemic failure where local interventions to the primary tumor or individual metastases were deemed futile. However, the emergence of the oligometastatic hypothesis—the concept of an intermediate state between localized and widespread metastatic disease—has fundamentally altered this clinical perspective.
With the advent of advanced molecular imaging, such as PSMA-PET/CT, clinicians can now identify patients with a limited number of metastatic lesions who might benefit from more aggressive, site-specific interventions. This shift toward a multimodal paradigm—combining systemic agents with local therapy (LT) and metastasis-directed therapy (MDT)—aims not just for palliation, but for significant extensions in progression-free and overall survival. A recent landmark umbrella review published in Cancer Treatment Reviews provides a high-level synthesis of the evidence supporting these strategies.
